vs
C4 Therapeutics, Inc.（CCCC）与RIVERVIEW BANCORP INC（RVSB）财务数据对比。点击上方公司名可切换其他公司
RIVERVIEW BANCORP INC的季度营收约是C4 Therapeutics, Inc.的1.3倍（$14.0M vs $11.0M），RIVERVIEW BANCORP INC净利率更高（9.8% vs -186.0%，领先195.8%），C4 Therapeutics, Inc.同比增速更快（112.8% vs 10.4%），过去两年C4 Therapeutics, Inc.的营收复合增速更高（90.4% vs 24.6%）
C4 Therapeutics是一家临床阶段生物制药企业，专注于开发靶向蛋白降解疗法，用于治疗癌症及其他存在重大未满足医疗需求的严重疾病。公司依托自有专利TORPEDO平台设计小分子降解剂清除致病蛋白，目前拥有多条肿瘤领域研发管线，并与头部制药企业达成战略合作。
Riverview Bancorp Inc.是一家总部位于美国的银行控股公司，主营个人与商业银行业务，服务覆盖太平洋西北地区，提供存款、消费贷款、住房抵押贷款、商业信贷及小企业金融等产品，服务零售客户与本地企业群体。
CCCC vs RVSB — 直观对比
营收规模更大
RVSB
是对方的1.3倍
$11.0M
营收增速更快
CCCC
高出102.4%
10.4%
净利率更高
RVSB
高出195.8%
-186.0%
两年增速更快
CCCC
近两年复合增速
24.6%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $11.0M | $14.0M |
| 净利润 | $-20.5M | $1.4M |
| 毛利率 | — | — |
| 营业利润率 | -210.1% | 12.4% |
| 净利率 | -186.0% | 9.8% |
| 营收同比 | 112.8% | 10.4% |
| 净利润同比 | 40.7% | 11.8% |
| 每股收益（稀释后） | $-0.09 | $0.07 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CCCCRVSB
| Q4 25 | $11.0M | $14.0M | ||
| Q3 25 | $11.2M | $13.6M | ||
| Q2 25 | $6.5M | $13.3M | ||
| Q1 25 | $7.2M | $12.9M | ||
| Q4 24 | $5.2M | $12.7M | ||
| Q3 24 | $15.4M | $12.8M | ||
| Q2 24 | $12.0M | $12.2M | ||
| Q1 24 | $3.0M | $9.0M |
净利润CCCCRVSB
| Q4 25 | $-20.5M | $1.4M | ||
| Q3 25 | $-32.2M | $1.1M | ||
| Q2 25 | $-26.0M | $1.2M | ||
| Q1 25 | $-26.3M | $1.1M | ||
| Q4 24 | $-34.6M | $1.2M | ||
| Q3 24 | $-24.7M | $1.6M | ||
| Q2 24 | $-17.7M | $966.0K | ||
| Q1 24 | $-28.4M | $-3.0M |
营业利润率CCCCRVSB
| Q4 25 | -210.1% | 12.4% | ||
| Q3 25 | -306.4% | 10.2% | ||
| Q2 25 | -441.0% | 11.7% | ||
| Q1 25 | -402.9% | 11.3% | ||
| Q4 24 | -728.4% | 12.4% | ||
| Q3 24 | -183.9% | 15.5% | ||
| Q2 24 | -178.6% | 10.0% | ||
| Q1 24 | -1060.2% | -47.5% |
净利率CCCCRVSB
| Q4 25 | -186.0% | 9.8% | ||
| Q3 25 | -286.4% | 8.1% | ||
| Q2 25 | -402.6% | 9.2% | ||
| Q1 25 | -363.7% | 8.9% | ||
| Q4 24 | -667.8% | 9.7% | ||
| Q3 24 | -160.6% | 12.2% | ||
| Q2 24 | -147.6% | 7.9% | ||
| Q1 24 | -933.2% | -34.7% |
每股收益（稀释后）CCCCRVSB
| Q4 25 | $-0.09 | $0.07 | ||
| Q3 25 | $-0.44 | $0.05 | ||
| Q2 25 | $-0.37 | $0.06 | ||
| Q1 25 | $-0.37 | $0.05 | ||
| Q4 24 | $-0.50 | $0.06 | ||
| Q3 24 | $-0.35 | $0.07 | ||
| Q2 24 | $-0.26 | $0.05 | ||
| Q1 24 | $-0.41 | $-0.14 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $74.6M | $28.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $256.6M | $164.2M |
| 总资产 | $359.1M | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CCCCRVSB
| Q4 25 | $74.6M | $28.6M | ||
| Q3 25 | $58.8M | $32.8M | ||
| Q2 25 | $78.2M | $34.2M | ||
| Q1 25 | $51.3M | $29.4M | ||
| Q4 24 | $55.5M | $25.3M | ||
| Q3 24 | $59.6M | $31.0M | ||
| Q2 24 | $73.1M | $27.8M | ||
| Q1 24 | $89.7M | $23.6M |
股东权益CCCCRVSB
| Q4 25 | $256.6M | $164.2M | ||
| Q3 25 | $154.4M | $163.5M | ||
| Q2 25 | $174.1M | $162.0M | ||
| Q1 25 | $195.1M | $160.0M | ||
| Q4 24 | $216.0M | $158.3M | ||
| Q3 24 | $242.7M | $160.8M | ||
| Q2 24 | $247.1M | $155.9M | ||
| Q1 24 | $258.3M | $155.6M |
总资产CCCCRVSB
| Q4 25 | $359.1M | $1.5B | ||
| Q3 25 | $265.5M | $1.5B | ||
| Q2 25 | $296.5M | $1.5B | ||
| Q1 25 | $319.5M | $1.5B | ||
| Q4 24 | $349.6M | $1.5B | ||
| Q3 24 | $376.1M | $1.5B | ||
| Q2 24 | $381.1M | $1.5B | ||
| Q1 24 | $398.4M | $1.5B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-22.1M | $-506.0K |
| 自由现金流经营现金流 - 资本支出 | — | $-736.0K |
| 自由现金流率自由现金流/营收 | — | -5.2% |
| 资本支出强度资本支出/营收 | — | 1.6% |
| 现金转化率经营现金流/净利润 | — | -0.37× |
| 过去12个月自由现金流最近4个季度 | — | $20.4M |
8季度趋势，按日历期对齐
经营现金流CCCCRVSB
| Q4 25 | $-22.1M | $-506.0K | ||
| Q3 25 | $-31.2M | $16.8M | ||
| Q2 25 | $-12.1M | $-697.0K | ||
| Q1 25 | $-33.3M | $8.3M | ||
| Q4 24 | $-17.9M | $2.2M | ||
| Q3 24 | $-24.1M | $764.0K | ||
| Q2 24 | $-5.0M | $5.4M | ||
| Q1 24 | $-18.1M | $12.8M |
自由现金流CCCCRVSB
| Q4 25 | — | $-736.0K | ||
| Q3 25 | $-31.6M | $16.4M | ||
| Q2 25 | — | $-773.0K | ||
| Q1 25 | — | $5.6M | ||
| Q4 24 | $-17.9M | $1.9M | ||
| Q3 24 | $-24.1M | $-1.4M | ||
| Q2 24 | $-5.2M | $5.3M | ||
| Q1 24 | — | $7.1M |
自由现金流率CCCCRVSB
| Q4 25 | — | -5.2% | ||
| Q3 25 | -281.5% | 120.1% | ||
| Q2 25 | — | -5.8% | ||
| Q1 25 | — | 43.1% | ||
| Q4 24 | -346.5% | 15.0% | ||
| Q3 24 | -157.2% | -11.3% | ||
| Q2 24 | -43.1% | 43.7% | ||
| Q1 24 | — | 79.0% |
资本支出强度CCCCRVSB
| Q4 25 | — | 1.6% | ||
| Q3 25 | 3.7% | 2.9% | ||
| Q2 25 | — | 0.6% | ||
| Q1 25 | — | 21.0% | ||
| Q4 24 | 0.1% | 2.4% | ||
| Q3 24 | 0.1% | 17.3% | ||
| Q2 24 | 1.6% | 0.9% | ||
| Q1 24 | 0.0% | 62.0% |
现金转化率CCCCRVSB
| Q4 25 | — | -0.37× | ||
| Q3 25 | — | 15.25× | ||
| Q2 25 | — | -0.57× | ||
| Q1 25 | — | 7.20× | ||
| Q4 24 | — | 1.79× | ||
| Q3 24 | — | 0.49× | ||
| Q2 24 | — | 5.63× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
